Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

计划入组 38 人 · 首次发布于 2026 年 1 月 20 日

RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)

计划入组 39 人 · 首次发布于 2019 年 12 月 10 日

Anti-PD-1 +/- RT for MSI-H Solid Tumors

首次发布于 2019 年 6 月 27 日

Sofusa anti-PD-1

89Zr-anti-PD-1

Recombinant anti-PD-1 humanized monoclonal antibody

Biosimilar Collaborations Ireland Ltd.

Ireland

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

Teva and mAbxience Expand Partnership with New Anti-PD-1 Oncology Biosimilar

Teva and mAbxience Expand Partnership with New PD-1 Biosimilar Candidate

Golidocitinib Plus PD-1 Antibodies Shows Promise in NSCLC Patients After Anti-PD-1 Therapy Failure